Head-to-head · WeighScore
Ivim Health vs Steady State Health
The verdict
Ivim Health takes it — 59.6/100 to 54.9/100.
Ivim Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Ivim Health is a telehealth weight-loss programme selling compounded semaglutide starting at $149/mo and compounded tirzepatide starting at $224/mo, each quoted with medication and programme charges included.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Ivim Health | Steady State Health |
|---|---|---|
| WeighScore | 59.6/100 | 54.9/100 |
| Grade | C | C |
| Scorecard rank | #338 | #451 |
| Semaglutide | $149/mo (starting dose, medication and programme fee, compounded) | Not disclosed |
| Tirzepatide | $224/mo (starting dose, medication and programme fee, compounded) | Not disclosed |
| Coverage | Coverage not published | 2 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #338 · C
Strengths
- Both molecules are priced on one page, each quoted as medication and programme charge included rather than as a bare drug price
- A six-month commitment brings tirzepatide down to $133/mo, and the term is published rather than hidden
- The first month of the membership is free
Where it loses points
- A $75/mo membership is marketed as a separate product, and whether it is charged on top of the $149 medication rate is not stated anywhere we could find
- The $133/mo tirzepatide rate advertised on the homepage requires a six-month commitment; the month-to-month rate is $224
- Both figures are 'starting at' rates, so the cost of a titrated dose is not published
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #451 · C
Strengths
- Prescribes semaglutide or tirzepatide within a perimenopause and menopause hormone-and-metabolic care plan
- Care delivered by a named women's-health nurse practitioner (Josie Cowburn, DNP, FNP-C)
- Transparent flat program fee from $139/mo, with a $99/mo standalone GLP-1 support option
Where it loses points
- Available only to Oregon and Washington residents
- GLP-1 medication is billed separately by the pharmacy and not included in the program fee
- Dispensing pharmacy is not publicly named
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.